Quality control guidelines for clinical-grade human induced pluripotent stem cell lines

Use of clinical-grade human induced pluripotent stem cell (iPSC) lines as a starting material for the generation of cellular therapeutics requires demonstration of comparability of lines derived from different individuals and in different facilities. This requires agreement on the critical quality a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Regenerative medicine 2018-10, Vol.13 (7), p.859-866
Hauptverfasser:	Sullivan, Stephen, Stacey, Glyn N, Akazawa, Chihiro, Aoyama, Naoki, Baptista, Ricardo, Bedford, Patrick, Bennaceur Griscelli, Annelise, Chandra, Amit, Elwood, Ngaire, Girard, Mathilde, Kawamata, Shin, Hanatani, Tadaaki, Latsis, Theodoros, Lin, Stephen, Ludwig, Tenneille E, Malygina, Tamara, Mack, Amanda, Mountford, Joanne C, Noggle, Scott, Pereira, Lygia V, Price, Jack, Sheldon, Michael, Srivastava, Alok, Stachelscheid, Harald, Velayudhan, Shaji R, Ward, Natalie J, Turner, Marc L, Barry, Jacqueline, Song, Jihwan
Format:	Artikel
Sprache:	eng
Schlagworte:	Accreditation Agreements Bacteriology Cancer Cell Line Cell- and Tissue-Based Therapy - standards clinical-grade induced pluripotent stem cells Flow cytometry Gene expression good manufacturing practice Humans Induced Pluripotent Stem Cells - cytology Induced Pluripotent Stem Cells - immunology Induced Pluripotent Stem Cells - microbiology Laboratories minimum testing requirements Mutation Practice Guidelines as Topic Product testing Quality Control quality control attributes Stem cells Workshops
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!